Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.
Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392:2052–90.
United States Renal Data System. 2019 USRDS Annual Data Report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2019. https://www.usrds.org/media/2371/2019-executive-summary.pdf. Accessed 13 Oct 2021.
Folkerts K, Petruski-Ivleva N, Kelly A, et al. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database. J Manag Care Spec Pharm. 2020;26:1506–16.
Escobar C, Palacios B, Aranda U, et al. Costs and healthcare utilisation of patients with chronic kidney disease in Spain. BMC Health Serv Res. 2021;21:536.
Cabrera CS, Lee AS, Olsson M, et al. Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes. Kidney Int Rep. 2020;5:1651–60.
Huang Y-J, Hsu Y-L, Chuang Y-H, Lin HY-H, Chen Y-H, Chan T-C. Association between renal function and cardiovascular mortality: a retrospective cohort study of elderly from health check-up. BMJ Open. 2021;11:e049307.
Darlington O, Dickerson C, Evans M, et al. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney disease: evidence from a systematic literature review. Adv Ther. 2021;38:994–1010.
Gandjour A, Armsen W, Wehmeyer W, Multmeier J, Tschulena U. Costs of patients with chronic kidney disease in Germany. PLoS ONE. 2020;15:e0231375.
Ingrasciotta Y, Sultana J, Formica D, et al. Direct healthcare costs of chronic kidney disease management in Italy: what cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents? Pharmacoepidemiol Drug Saf. 2021;30:65–77.
Zhang H, Zhang C, Zhu S, Ye H, Zhang D. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China. BMC Health Serv Res. 2020;20:122.
National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:91–111.
Murton M, Goff-Leggett D, Bobrowska A, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Adv Ther. 2021;38:180–200.
Oshima M, Shimizu M, Yamanouchi M, et al. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021;17:740–50.
Vistisen D, Andersen GS, Hulman A, Persson F, Rossing P, Jørgensen ME. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria. Diabetes Care. 2019;42:1886–94.
Weldegiorgis M, de Zeeuw D, Li L, et al. Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy. Am J Kidney Dis. 2018;71:91–101.
Jun M, Harris K, Heerspink HJL, et al. Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: post hoc analysis from the ADVANCE trial. Diabetes Obes Metab. 2021;23:1420–5.
Ali I, Chinnadurai R, Ibrahim ST, Kalra PA. Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression. BMC Nephrol. 2021;22:82.
Kovesdy CP, Naseer A, Sumida K, et al. Abrupt decline in kidney function precipitating initiation of chronic renal replacement therapy. Kidney Int Rep. 2018;3:602–9.
Liu P, Quinn RR, Lam NN, et al. Progression and regression of chronic kidney disease by age among adults in a population-based cohort in Alberta, Canada. JAMA Netw Open. 2021;4:e2112828.
Yang L, Chu TK, Lian J, et al. Individualised risk prediction model for new-onset, progression and regression of chronic kidney disease in a retrospective cohort of patients with type 2 diabetes under primary care in Hong Kong. BMJ Open. 2020;10:e035308.
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398:786–802.
Afkarian M, Katz R, Bansal N, et al. Diabetes, kidney disease, and cardiovascular outcomes in the Jackson Heart Study. Clin J Am Soc Nephrol. 2016;11:1384–91.
Tuttle KR, Alicic RZ, Duru OK, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open. 2019;2:e1918169.
Deng Y, Li N, Wu Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. Front Endocrinol. 2021;12:809.
Duan J, Wang C, Liu D, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents: a cross-sectional survey. Sci Rep. 2019;9:10408.
Muskiet MHA, Wheeler DC, Heerspink HJL. New pharmacological strategies for protecting kidney function in type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7:397–412.
Garcia Sanchez JJ, Thompson J, Scott DA, et al. Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Adv Ther. 2022;39(1):193–220.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.
Neuen BL, Arnott C, Perkovic V, et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab. 2021;23:382–90.
Cherney DZI, Heerspink HJL, Frederich R, et al. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020;63:1128–40.
Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–54.
Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–31.
Sugrue DM, Ward T, Rai S, McEwan P, van Haalen HGM. Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design. Pharmacoeconomics. 2019;37:1451–68.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLOS Med. 2021;18:e1003583.
Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics. 2008;26:131–48.
Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5-26.
Covalence Research Ltd. Sourcerer.pro. 2021. https://sourcerer.pro. Accessed 10 Jan 2022.
Wickham H. ggplot2: elegant graphics for data analysis. Springer: New York; 2016. https://ggplot2.tidyverse.org.
Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4:1686.
Hester J. glue: interpreted string literals. 2020. https://CRAN.R-project.org/package=glue. Accessed 15 Oct 2021.
Bryan J, RStudio. googlesheets4: access Google Sheets using the Sheets API V4. 2021. https://CRAN.R-project.org/package=googlesheets4. Accessed 15 Oct 2021.
Pebesma E. Simple features for R: standardized support for spatial vector data. R J. 2018;10:439.
Iannone R, Cheng J, Schloerke B, RStudio. gt: easily create presentation-ready display tables. 2021. https://CRAN.R-project.org/package=gt. Accessed 15 Oct 2021.
Pedersen TL. Patchwork: the composer of plots. 2020. https://CRAN.R-project.org/package=patchwork. Accessed 9 Sep 2021.
Arnold JB, Daroczi G, Werth B, et al. ggthemes: extra themes, scales and geoms for “ggplot2”. 2021. https://CRAN.R-project.org/package=ggthemes. Accessed 15 Oct 2021.
Wilke CO. ggtext: improved text rendering support for “ggplot2”. 2020. https://CRAN.R-project.org/package=ggtext. Accessed 15 Oct 2021.
Brunson JC, Read QD. ggalluvial: alluvial plots in “ggplot2”. 2020. https://CRAN.R-project.org/package=ggalluvial. Accessed 15 Oct 2021.
Jeworutzki S, Giraud T, Lambert N, Bivand R, Pebesma E, Nowosad J. cartogram: create cartograms with R. 2020. https://CRAN.R-project.org/package=cartogram. Accessed 15 Oct 2021.
Zeileis A, Fisher JC, Hornik K, et al. colorspace: a toolbox for manipulating and assessing colors and palettes. J Stat Softw. 2020;96:1–49.
Zeileis A, Hornik K, Murrell P. Escaping RGBland: selecting colors for statistical graphics. Comput Stat Data Anal. 2009;53:3259–70.
Wickham H, Seidel D, RStudio. scales: scale functions for visualization. 2020. https://CRAN.R-project.org/package=scales. Accessed 15 Oct 2021.
South A. rnaturalearth: world map data from Natural Earth. 2017. https://CRAN.R-project.org/package=rnaturalearth. Accessed 15 Oct 2021.
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. https://www.R-project.org/. Accessed 13 Oct 2021.
Pedersen TL, Shemanarev M, Juricic T, Marusinec M, Garret S, RStudio. ragg: graphic devices based on AGG. 2021. https://CRAN.R-project.org/package=ragg. Accessed 15 Oct 2021.
Pedersen TL. Tidygraph: a tidy API for graph manipulation. 2020. https://CRAN.R-project.org/package=tidygraph. Accessed 23 Sep 2021.
Pedersen TL, RStudio. ggraph: an implementation of grammar of graphics for graphs and networks. 2021. https://CRAN.R-project.org/package=ggraph. Accessed 23 Sep 2021.
Csardi G, Nepusz T. The igraph software package for complex network research. Int J. 2006;Complex Syst:1695.
Borgatti SP. Centrality and network flow. Soc Netw. 2005;27:55–71.
McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29:2520–37.
Higgins JPT, White IR, Anzures-Cabrera J. Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Stat Med. 2008;27:6072–92.
Adarkwah CC, Gandjour A, Akkerman M, Evers SM. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in the Netherlands: a Markov model. PLoS ONE. 2011;6:e26139.
Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform. 2002;35:37–50.
Shao H, Fonseca V, Stoecker C, Liu S, Shi L. Novel risk engine for diabetes progression and mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). Pharmacoeconomics. 2018;36:1125–34.
Campbell HM, Boardman KD, Dodd MA, Raisch DW. Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model. Ann Pharmacother. 2007;41:1101–10.
McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin. 2006;22:121–9.
Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000;22:116–27.
CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–51.
Chen THH, Yen MF, Tung TH. A computer simulation model for cost–effectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res Clin Pract. 2001;54:37–42.
Quan J, Ng CS, Kwok HHY, et al. Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: a modeling study. PLOS Med. 2021;18:e1003692.
Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics. 2002;20(Suppl 1):31–42.
Willis M, Asseburg C, Slee A, Nilsson A, Neslusan C. Development and internal validation of a discrete event simulation model of diabetic kidney disease using CREDENCE trial data. Diabetes Ther. 2020;11:2657–76.
Critselis E, Vlahou A, Stel VS, Morton RL. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. Nephrol Dial Transpl. 2018;33:441–9.
Deerochanawong C, Vareesangthip K, Piyayotai D, Thongsuk D, Pojchaijongdee N, Permsuwan U. Cost-utility analysis of dapagliflozin as an add-on to standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in Thailand. Diabetes Ther. 2021;12:1947–63.
Delea TE, Sofrygin O, Palmer JL, et al. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J Am Soc Nephrol. 2009;20:2205–13.
Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of type II diabetes. Diabetologia. 2001;44:2140–55.
Mueller E, Maxion-Bergemann S, Gultyaev D, et al. Development and validation of the economic assessment of glycemic control and long-term effects of diabetes (EAGLE) model. Diabetes Technol Ther. 2006;8:219–36.
Willis M, Johansen P, Nilsson A, Asseburg C. Validation of the economic and health outcomes model of type 2 diabetes mellitus (ECHO-T2DM). Pharmacoeconomics. 2017;35:375–96.
Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract. 2000;50:S15–46.
Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131:660–7.
González JC, Walker JH, Einarson TR. Cost-of-illness study of type 2 diabetes mellitus in Colombia. Rev Panam Salud Publica. 2009;26:55–63.
Guinan K, Beauchemin C, Tremblay J, et al. Economic evaluation of a new polygenic risk score to predict nephropathy in adult patients with type 2 diabetes. Can J Diabetes. 2021;45:129–36.
Hayashino Y, Fukuhara S, Akizawa T, et al. Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. Diabetes Res Clin Pract. 2010;90:154–9.
Howard K, White S, Salkeld G, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health. 2010;13:196–208.
Steen Carlsson K, Persson U. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. J Med Econ. 2014;17:658–69.
Gozzoli V, Palmer AJ, Brandt A, Spinas GA. Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting. Swiss Med Wkly. 2001;131:303–10.
Tanaka S, Langer J, Morton T, et al. Developing a health economic model for Asians with type 2 diabetes based on the Japan Diabetes Complications Study and the Japanese Elderly Diabetes Intervention Trial. BMJ Open Diabetes Res Care. 2021;9:e002177.
Kansal A, Reifsnider OS, Proskorovsky I, et al. Cost-effectiveness analysis of empagliflozin treatment in people with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019;36:1494–502.
Kazemian P, Wexler DJ, Fields NF, Parker RA, Zheng A, Walensky RP. Development and validation of PREDICT-DM: a new microsimulation model to project and evaluate complications and treatments of type 2 diabetes mellitus. Diabetes Technol Ther. 2019;21:344–55.
van der Heijden AAWA, Feenstra TL, Hoogenveen RT, et al. Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model. Diabet Med. 2015;32:1580–7.
Zhou H, Isaman DJM, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care. 2005;28:2856–63.
Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1997;20:725–34.
Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transpl. 2003;18:2059–66.
Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care. 2004;27:1897–903.
Palmer AJ, Chen R, Valentine WJ, et al. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes Metab. 2006;32:69–76.
Schramm W, Sailer F, Pobiruchin M, Weiss C. PROSIT Open Source Disease Models for diabetes mellitus. Stud Health Technol Inform. 2016;226:115–8.
Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care. 1996;19:1051–61.
Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther. 2003;25:2102–19.
Sakthong P, Tangphao O, Eiam-Ong S, et al. Cost-effectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology. 2001;6:71–7.
Smith DG, Nguyen AB, Peak CN, Frech FH. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. J Manag Care Pharm. 2004;10:26–32.
Srisubat A, Sriratanaban J, Ngamkiatphaisan S, Tungsanga K. Cost-effectiveness of annual microalbuminuria screening in Thai diabetics. Asian Biomed. 2014;8:371–9.
Nagy B, Zsólyom A, Nagyjánosi L, et al. Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. Diabetes Metab Res Rev. 2016;32:710–29.
Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32.
Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–59.
Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925–33.
Leal J, Alva M, Gregory V, et al. Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). Diabet Med. 2021;38:e14656.
van Os N, Niessen LW, Bilo HJ, Casparie AF, van Hout BA. Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. Health Policy. 2000;51:135–47.
Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:788–95.
Watada H, Sakamaki H, Yabe D, et al. Cost-effectiveness analysis of linagliptin in Japan based on results from the Asian subpopulation in the CARMELINA® trial. Diabetes Ther. 2020;11:1721–34.
Wu B, Zhang S, Lin H, Mou S. Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis. J Diabetes Invest. 2018;9:152–61.
Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606–17.
Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520–6.
Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O’Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus: a population-based study in Rochester. Minnesota Ann Intern Med. 1989;111:788–96.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.
Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617–22.
ACCORD Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
Leibson CL, O’Brien PC, Atkinson E, Palumbo PJ, Melton LJ. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am J Epidemiol. 1997;146:12–22.
Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ. 1987;294:1651–4.
Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985;78:785–94.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.
Loh PT, Toh MPHS, Molina JA, Vathsala A. Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster. Nephrology. 2015;20:216–23.
Iseki K, Ikemiya Y, Kinjo K, Iseki C, Takishita S. Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa. Japan Clin Exp Nephrol. 2004;8:250–6.
Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019;131(1):31–42.
Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10(1):1–10.
Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences. Am J Kidney Dis. 2010;55:452–62.
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78.
Porrini E, Ruggenenti P, Mogensen CE, et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3:382–91.
MacIsaac RJ, Ekinci EI. Progression of diabetic kidney disease in the absence of albuminuria. Diabetes Care. 2019;42:1842–4.
Li L, Astor BC, Lewis J, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59:504–12.
Mann JFE, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8:880–93.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
Škrtić M, Cherney DZI. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2015;24:96–103.
Collard D, Brouwer TF, Olde Engberink RHG, Zwinderman AH, Vogt L, van den Born B-JH. Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy: a post hoc analysis of the SPRINT and ACCORD-BP randomized controlled trials. Hypertension. 2020;75:1205–12.
Chen DC, McCallum W, Sarnak MJ, Ku E. Intensive BP control and eGFR declines: are these events due to hemodynamic effects and are changes reversible? Curr Cardiol Rep. 2020;22:117.
Beddhu S, Shen J, Cheung AK, et al. Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT. J Am Soc Nephrol. 2019;30:1523–33.
Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91:683–90.
Davis S, Stevenson M, Tappenden P, Wailoo A. NICE DSU technical support document 15: cost-effectiveness modelling using patient-level simulation. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2014. p. 62. http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD15_Patient-level_simulation.pdf. Accessed 17 Oct 2021.
Katsikopoulos KV, Şimşek Ö, Buckmann M, Gigerenzer G. Transparent modeling of influenza incidence: big data or a single data point from psychological theory? Int J Forecast. 2021. https://doi.org/10.1016/j.ijforecast.2020.12.006.
Durkin M, Blais J. Linear projection of estimated glomerular filtration rate decline with canagliflozin and implications for dialysis utilization and cost in diabetic nephropathy. Diabetes Ther. 2021;12:499–508.
Zhu Y, Sidell MA, Arterburn D, et al. Racial/ethnic disparities in the prevalence of diabetes and prediabetes by BMI: Patient Outcomes Research To Advance Learning (PORTAL) multisite cohort of adults in the U.S. Diabetes Care. 2019;42:2211–2219.
Cheng YJ, Kanaya AM, Araneta MRG, et al. Prevalence of diabetes by race and ethnicity in the United States, 2011–2016. JAMA. 2019;322:2389–98.
Ezzatvar Y, Ramírez-Vélez R, Izquierdo M, García-Hermoso A. Racial differences in all-cause mortality and future complications among people with diabetes: a systematic review and meta-analysis of data from more than 2.4 million individuals. Diabetologia. 2021;64:2389–2401.
Yu D, Zhao Z, Osuagwu UL, et al. Ethnic differences in mortality and hospital admission rates between Māori, Pacific, and European New Zealanders with type 2 diabetes between 1994 and 2018: a retrospective, population-based, longitudinal cohort study. Lancet Global Health. 2021;9:e209–17.
Patzer RE, McClellan WM. Influence of race, ethnicity and socioeconomic status on kidney disease. Nat Rev Nephrol. 2012;8:533–41.
Gama RM, Clery A, Griffiths K, et al. Estimated glomerular filtration rate equations in people of self-reported black ethnicity in the United Kingdom: inappropriate adjustment for ethnicity may lead to reduced access to care. PLoS ONE. 2021;16:e0255869.
Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(2):268–288.e1.
Ma RCW, Chan JCN. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64–91.
Li X, Zhang Q, Zhou X, et al. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials. Aging. 2021;13:12748–65.
Dadwani RS, Laiteerapong N. Economic simulation modeling in type 2 diabetes. Curr Diab Rep. 2020;20:24.
Inagaki N, Yang W, Watada H, et al. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. Diabetol Int. 2020;11:129–41.
Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics. 2011;29:35–49.
Woodcock J, Araojo R, Thompson T, Puckrein GA. Integrating research into community practice — toward increased diversity in clinical trials. N Engl J Med. 2021;385:1351–3.
Cohen JF, Korevaar DA, Wang J, Spijker R, Bossuyt PM. Should we search Chinese biomedical databases when performing systematic reviews? Syst Rev. 2015;4:23.
Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75:84–104.